Last Updated : May 11, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
Brand Name | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received Sort descending | Date Recommendation Issued |
---|---|---|---|---|---|---|
Jorveza | budesonide | Eosinophilic esophagitis, adults | Reimburse with clinical criteria and/or conditions | Complete | ||
Tecentriq & Avastin | Atezolizumab & Bevacizumab | NSQ-NSCLC | Do not reimburse | Complete | ||
Entyvio | vedolizumab | Ulcerative Colitis | Reimburse with clinical criteria and/or conditions | Complete | ||
Rozlytrek | Entrectinib | ROS1-positive NSCLC | Reimburse with clinical criteria and/or conditions | Complete | ||
Blincyto | Blinatumomab | MRD+ ALL Resubmission | Reimburse with clinical criteria and/or conditions | Complete | ||
Duobrii | Halobetasol propionate and tazarotene | Psoriasis, moderate to severe plaque | Reimburse with clinical criteria and/or conditions | Complete | ||
Zejula | Niraparib | Ovarian Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
Xtandi | Enzalutamide | mHSPC | Reimburse with clinical criteria and/or conditions | Complete | ||
Soliris | eculizumab | Neuromyelitis optica spectrum disorder | Reimburse with clinical criteria and/or conditions | Complete | ||
Adcetris | Brentuximab Vedotin | Primary cutaneous anaplastic large cell Lymphoma (pcALCL) or CD30-expressing mycosis fungoides (MF) | Reimburse with clinical criteria and/or conditions | Complete |